Current perspectives on camptothecins in cancer treatment

British Journal of Cancer

Volumn 74, Issue 3, 1996, Pages 327-338

  Dancey, J ^a   Eisenhauer, E A ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

9 aminocamptothecin; Camptothecin; Irinotecan; Topoisomerase I inhibitor; Topotecan

Indexed keywords

9 AMINOCAMPTOTHECIN; ATROPINE; CAMPTOTHECIN; CISPLATIN; DIPHENHYDRAMINE; DNA TOPOISOMERASE; ETOPOSIDE; IRINOTECAN; LOPERAMIDE; LURTOTECAN; ONDANSETRON; TOPOTECAN; VINDESINE;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; EOSINOPHILIA; FATIGUE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; INTERSTITIAL PNEUMONIA; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MUCOSA INFLAMMATION; NEUTROPENIA; NONHUMAN; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; RASH; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA;

EID: 0030055094     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.362     Document Type: Review

References (146)

1. ABBRUZZESE JL, MADDEN T, SCHMIDT S, EATON G AND RABER MN. (1993). Phase I trial of topotecan (TT) administered by 24-hour infusion without and with G-CSF. (abstract 1957). Proc. Am. Assoc. Cancer Res., 34, 329.
2. ABIGERGES D, ARMAND JP, CHABOT CG, DA COSTA L, FADEL E, COTE C, HERAIT P AND GANDIA D. (1994). Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhoea. J. Natl Cancer Inst., 86, 446 449.
3. ANDOH T, ISHII K, SUZUKI Y, IKEGAMI Y, KUSUNOKI Y, TAKEMOTO Y AND OKADA K. (1987). Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc. Natl Acad. Sci. USA, 84, 5565 5569.
4. ARAKI E, ISHIKAWA M, IIGO M, KOIDE T, ITABASHI M AND HOSHI A. (1993). Relationship between development of diarrhoea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn. J. Cancer Res., 84, 697 702.
5. ARMSTRONG D, ROWINSKY E, DONEHOWER R, ROSENSHEIN N, WALCZAK J AND MCGUIRE W. (1995). A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer. (abstract 769). Proc. Am. Soc. Clin. Oncol., 14, 275.
6. BENEDETTI P, FIORANI P, CAPUANI L AND WANG JC. (1993). Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cystcine. Cancer Res., 53, 4343 4348.
7. BERTRAND R, O'CONNOR PM, KERRIGAN D AND POMMIER Y. (1992). Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur. J. Cancer, 28A, 743 748.
8. BLANEY SM, BALIS FM, COLE DE, CRAIG C, REID JM, AMES MM, KRAILO M, REAMAN G, HAMMOND D AND POPLACK DG. (1993). Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res., 53, 1032 1036.
9. BONNETERRE J, PION JM, ADENIS M, TUBIANA-HULIN M, TURSZ T, MARTY M AND MATHIEU-BOUF A. (1993). A phase II study of a new camptothecin analogue CPT-11 in previously treated advanced breast cancer patients. (abstract 179). Proc. Am. Soc. Clin. Oncol., 12, 94.
10. BUGAT R, SUC E, ROUGIER P, BECOUARN Y, NAIEFF I, YCHOU M, CULINE S, EXTRA JM, ADENIS A, GANEM G, MIOVANNINI M, MERROUCHE M, FERRERO F, CONROY T, DESPAX R, MOUSSEAU I, BEKRADA M, MATHIEU-BOUE A, MAHJOUBI M AND HERAIT P. (1994). CPT-11 (irinotecan) as second line therapy in advanced colorectal cancer (CRC): preliminary results of a multicentric phase II study. (abstract 586). Proc. Am. Soc. Clin. Oncol., 13, 200.
11. BUGAT R, ROUGIER P, DOUILLARD JY, BRUNET R, YCHOU M, ADENIS A, MARTY M, SELTZ JF, CONROY T, MAROUCHE Y, GANEM G, NAMER M, BURKI F, MOUSSEAU M AND MAHJOUBI M. (1995). Efficacy of irinotecan HCI (CPT-11) in patients with metastatic colorectal cancer after progression while receiving a 5FU-based chemotherapy. (abstract 567). Proc. Am. Soc. Clin. Oncol., 14, 222.
12. BURRIS HA, HANAUSKE AR, JOHNSON RK, MARSHALL MH, KUHN JG, HILSENBECK SG. AND VON HOFF DD. (1992). Activity of topotecan. a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J. Natl Cancer Inst., 84, 1816-1820.
13. BURRIS HA, III, AWADA A, KUHN JG, ECKARDT JR, COBB PW, RINALDI DA, FIELDS SF, SMITH L AND VON HOFF DD. (1994). Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anti-cancer Drugs, 5, 394 402.
14. CHAMPOUX J. (1976). Evidence for an intermediate with singlestand break in the reaction catalyzed by the DNA untwisting enzyme. Proc. Natl Acad. Sci. USA, 73, 3488 3491.
15. CHANG AY, GARROW G, BOROS L, ASBURY R, PANDYA K AND KENG P. (1995). Clinical and laboratory studies of topotecan in breast cancer. (abstract 118). Proc. Am. Soc. Clin. Oncol., 14, 105.
16. CHEN AY, YU C, POTMESIL M, WALL ME, WANI MC AND LIU LF. (1991). Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res., 51, 6039 6044.
17. CHEVALLIER B, L'HOMME C, DIERAS V, VENNIN PH, CHAU, VERGNE J, REBATTU P, FUMOLEAU P, ROCHE H, KRAKOWSKI Y, LENTZ MA, MATHIEU BOUE A AND VAN GLABBEKE M. (1995). Phase II trial of CPT11 in advanced cervical carcinoma. (abstract 737). Proc. Am. Clin. Oncol., 14, 267.
18. CLAVEL M, MATHIEU-BOUE A, DUMORTIER A, CHABOT GG, COTE C, BISSERY MC AND MARTY M. (1992). Phase I study of CPT-11 administered as a daily infusion for 3 consecutive days. (abstract 1568). Proc. Am. Assoc. Cancer Res., 33, 262.
19. CONTI JA, KAMENY N, SALTZ L, TONG W, CHOU TC AND PULLIAM M. (1994). Irinotecan (CPT-11) is an active agent in untreated patients (pts) with metastatic colorectal cancer (CRC). (abstract 565). Proc. Am. Soc. Clin. Oncol., 13, 195.
20. CREEMERS GJ, WANDERS J, CALABRESI F, VALENTIN S, DIRIX LY, SCHOFFSK IP, FRANKLIN H, MCDONALD M AND VERWEIJ J. (1994). Topotecan in colorectal cancer, a phase II study of the EORTC early clinical trials group. (suppl. 5, abstract 464). Ann. Oncol., 5, 191.
21. CREEMERS GJ, SCHELLENS JHM, PLANTING ASTH, VD BURG MEL., DEBOER-DENNERT M, HARTEVELD M, MCDONALD M, STOTER G AND VERWEIJ J. (1995). Cumulative myelosuppression of topotecan (T) administered as a 21-day continuous infusion in patients with colorectal cancer. (abstract 354). Proc. Am. Soc. Clin. Oncol., 14, 167.
22. DAHUT W, BRILLHART N, TAKIMOTO C, ALLEGRA C, HAMILTON JM, SORENSEN S, ARBUCK S, CHEN A AND GREM J. (1994). A phase I trial of 9-aminocamptothecin (9-AC) in adult patients with solid tumors. (abstract 345). Proc. Am. Soc. Clin. Oncol., 13, 138.
23. DE FORNI M, BUGAT R, CHABOT GG, CULINE S, EXTRA J-M, GOUYETTE A, MADELAINE I, MARTY ME AND MATHIEU-BOUE A. (1994). Phase I and pharmacokinetic study of the camptothecin derivative irinotecan administered on a weekly schedule in cancer patients. Cancer Res., 54, 4347 4354.
24. DEL BINO G, LASSOTA P AND DARZYNKIEWICZ Z. (1991). The S-phase cytotoxicity of camptothecin. Exp. Cell Res., 193, 27 35.
25. DEL BINO G, BRUNO S, YI PN AND DARZYNKIEWICZ Z. (1992). Apoptotic cell death triggered by camptothecin or teniposide. The cell cycle specificity and effects of ionizing radiation. Cell Proliferation, 25, 537-548.
26. DOUILLARD JY, IBRAHIM N, RIVIERE A, SPAETH D, CHOMY P, SOUSSAN K AND MATHIEU-BOUE A. (1995). Phase II study of CPT-11 in non small cell lung cancer (NSCLC). (abstract 1118). Proc. Am. Soc. Clin. Oncol., 14, 365.
27. ECKARDT JR, BURRIS HA, VON HOFF DD, RODRIGUEZ GI, FIELDS SM, ROTHENBERG ML, MOORE TD, HODGES S, WEISS GR, COBB P, RINALDI D, KUHN JG, FORD J AND GANAPATHI R. (1994). Measurement of tumor topoisomerase I and II levels during the sequential administration of topotecan and etoposide. (abstract 358). Proc. Am. Soc. Clin. Oncol., 13, 141.
28. ECKARDT JR, RODRIGUEZ GI, BURRIS HA, WISSEL PS, FIELDS SM, ROTHENBERG ML, SMITH L, THURMAN A, KUNKA RL, DEPEE SP, LITTLEFIELD D, WHITE LJ AND VON HOFF DD. (1995). A phase I and pharmacokinetic study of the topoisomerase I inhibitor GG211. (abstract 1544). Proc. Am. Soc. Clin. Oncol., 14, 476.
29. EISENHAUER EA, WAINMAN N, BOOS G, MACDONALD D AND BRAMWELL V. (1994). Phase II trials of topotecan in patients (pts) with malignant glioma and soft tissue sarcoma. (abstract 488). Proc. Am. Soc. Clin. Oncol., 13, 175.
30. EMERSON DL, MCINTYRE G, LUZZIO MJ AND WISSEL PS. (1994). Pre-clinical anti tumor activity of a novel water-soluble camptothecin analog, (GI147211C). (suppl. 5, abstract 441). Ann. Oncol., 5, 185.
31. EMERSON DL, BESTERMAN JM, BROWN HR, EVANS MG, LEITNER PP, LUZZIO MJ, SHAFFER JE, STERNBACH DD, UEHLING D AND VUONG A. (1995). In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Cancer Res., 55, 603-609.
32. FRIEDMAN HS, HOUGHTON PJ, SCHOLD SC, KEIR S AND BIGNER DD. (1994). Activity of 9-dimethylaminomethyl-10-hydroxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother. Pharmacol., 34, 171-174.
33. FUJIWARA Y, YAMAKIDO M, FUKUOKA M, KUDOH S, FURUSE K, IKEGAMI H, ARIYOSHE Y FOR THE WEST JAPAN LUNG CANCER STUDY GROUP. (1994). Phase II study of irinotecan (CPT-11) and cisplatin (CDDP) in patients with small cell lung cancer (SCLC). (abstract 1110). Proc. Am. Soc. Clin. Oncol., 13, 335.
34. FUKUOKA M, NEGORO S, NIITANI H, FURUE H, HASEGAWA K, HARA Y, HARA N, AND TAGUCHI T. (1990). A phase I study of weekly administration of CPT-11 in lung cancer. Gan to Kagaku Ryoho, 17, 993-997.
35. FUKUOKA M., NIITANI H, SUZUKI A, MOTOMIYA M, HASEGAWA K, NISHIWAKI Y, KURIYAMA T, ARIYOSHI Y, NEGORO S, MASUDA N, NAKAJIMA S, TAGUCHI T. (1992). A phase II study of CPT-11, a new derivative of camptothecin. for previously untreated non-small-cell lung cancer. J. Clin. Oncol., 10, 16-20.
36. FURUTA T AND YOKOKURA T. (1990). Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative. Gan to Kagaku Ryoho, 17, 121-130.
37. FUTATSUKI K, WAKUI A, NAKAO I, SAKATA Y, KAMBE M, SHIMADA Y, YOSHINO M, TAGUCHI T AND OGAWA N. (1994). Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan to Kagaku Ryoho. 21, 1033-1038.
38. GANDIA D, ABIGERGES D, ARMAND JP, CHABOT G, DA COSTA L, DE FORNI M, MATHIEU-BOUE A AND HERAIT P. (1993). CPT-11-induced cholinergic effects in cancer patients. J. Clin. Oncol., 11, 196-197.
39. GIANTONIO BJ, KOSIEROWSKI R, RAMSEY HE, FOX SC, MCALEER CA, ROETHKE S, OZOLS RF AND HUDES GR. (1993). Phase II study of topotecan (TT) for hormone refractory prostate cancer (HRPC). (abstract 774). Proc. Am. Soc. Clin. Oncol., 12, 247.
40. GIOVANELLA BC, STEHLIN JS, WALL ME, WANI MC, NICHOLAS AW, LIU LF, SILBER R AND POTMESIL M. (1989). DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science, 246, 1046-1048.
41. GIOVANELLA BC, HINZ HR, KOZIELSKI AJ, STEHLIN JS JR, SILBER R AND POTMESIL M. (1991). Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(s)-camptothecin. Cancer Res., 51, 3052-3055.
42. GONG J, LI X AND DARZYNKIEWICZ Z. (1993). Different patterns of apoptosis of HL-60 cells induced by cycloheximide and camptothecin. J. Cell Physiol., 157, 263-270.
43. GOTO K, NISHIWAKI Y, SAIJO N, NAKABAYASHI T, KAWAKAMI Y, FUJITA A, TOBISE K, ABE S, SUZUKI S, TSUCHIZY S, TAKAHASHI Y, HAYASHI I, NODA K, KURITA Y, MATSUDA Y, TAMURA T AND SHIMOYAMA M. (1995). A phase II study of irinotecan (CPT-11) and etoposide (VP-16) for metastatic non-small cell lung cancer (NSCLC): Japanese Clinical Oncology Group (JCOG) trial. (abstract 1108). Proc. Am. Soc. Clin. Oncol., 14, 362.
44. GOTTLEIB JA AND LUCE JK. (1972). Treatment of malignant melanoma with camptothecin (MSC-100880). Cancer Chemother. Rep., 56, 103-105.
45. GROCHOW LB, SLICHENMYER W, ROWINSKY E, DONEHOWER R, FORASTIERE A AND CHEN T-L. (1994). Phase I clinical and pharmacologic study of topotecan (top) in patients with hepatic or renal dysfunction. (suppl. 5, abstract 462). Ann. Oncol., 5, 191.
46. GUPTA E, LESTINGI TM, MICK R, RAMIREZ J, VOKES EE AND RATAIN MJ. (1994). Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res., 54, 3723-3725.
47. HAAS NB, LACRETA FP, WALCZAK J, HUDES GR, BRENNAN JM, OZOLS RF AND O'DWYER PJ. (1994). Phase I pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res., 54, 1220-1226.
48. HAGIPANTELLI R, SALIBA F, MISSET JL, GIACCHETTI S, BRAIN E, BERTHEAULT-CVITKOVIC F, VASSAL G, BONNAY M, BASTIAN G, COTE C, MAHJOUBI M, HERAIT P AND CVITKOVIC E. (1995). Pathophysiology and therapy of irinotecan (CPT-11) induced delayed onset diarrhea (DD): a prospective assessment. (abstract 1499). Proc. Am. Soc. Clin. Oncol., 14, 464.
49. HASEGAWA K, HISHIMURA R, FUKUOKA M, FURUSE K, HASEGAWA K, HINO M AND NIITANI H. (1993). Phase I and pharmacologic evaluation of topotecan on a 30 minute infusion. (abstract 2514). Proc. Am. Assoc. Cancer Res., 34, 421.
50. HENDRICKS CB, ROWINSKY EK, GROCHOW LB, DONEHOWER RC AND KAUFMANN SH. (1992). Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864). a new camptothecin analogue. Cancer Res., 52, 2268 2278.
51. HERTZBERG RP, CARANFA MJ AND HECHT SM. (1989a). On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry. 28, 4629-4638.
52. HERTZBERG RP, CARANFA MJ, HOLDEN KG, JAKAS DR, GALLAGHER G, MATTERN MR, MONG SM, BARTUS JO, JOHNSON RK AND KINGSBURY WD. (1989b). Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem., 32, 715-720.
53. HOCHSTER H, LIEBES L, SPEYER J, SORICH J, TAUBES B, ORATZ R, WERNZ J, CHACHOUA A, RAPHAEL B, VINCI RZ AND BLOOM RH. (1994). Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J. Clin. Oncol., 12, 553-559.
54. HOUGHTON PJ, CHESHIRE PJ, HALLMAN JC, BISSERY MC, MATHIEU-BOUE A AND HOUGHTON JA. (1993). Therapeutic-efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumours with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res., 53, 2823-2829.
55. HSIANG YH AND LIU LF. (1988). Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res., 48, 1722-1726.
56. HSIANG YH, LIU LF, WALL ME, WANI MC, NICHOLAS AW, MANIKUMAR G, KIRSCHENBAUM S, SILBER R AND POTMESIL M. (1989). DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res., 49, 4385 4389.
57. HUTSON PR, KIM K, JOHNSON D AND SCHILLER JH. (1995). Pharmacodynamic evaluation of the response of extensive stage small cell lung cancer to topotecan. (abstract 1481). Proc. Am. Soc. Clin. Oncol., 14, 460.
58. ILSON D, MOTZER RJ, O'MOORE P, NANUS D, BOSL GJ (1993). A phase II trial of topotecan in advanced renal cell carcinoma. (abstract 779). Proc. Am. Soc. Clin. Oncol., 12, 248.
59. JANIK J, MILLER L, SMITH J, II, KOPP W, ALVORD G, GAUSE B, CURIT B, URBA WJ AND LONGO DL. (1993). Prechemotherapy granulocyte-macrophage colony stimulating factor (GM-CSF) prevents topotecan-induced neutropenia. (abstract 1507). Proc. Am. Soc. Clin. Oncol., 12, 437.
60. JAXEL C, KOHN KW, WANI MC, WALL ME AND POMMIER Y. (1989). Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res., 49, 1465-1469.
61. KANG MC, BANKSTON DD, ERICKSON GA, FANG FG, LACKEY JW, LEWIS GS, LICHTY ME, LOWERY MW, MADER C, MCDOUGAL DL, MOOK RA, PARTRIDGE JJ AND XIE S. (1993). Total synthesis of the novel water soluble camptothecin analog GI 147211C, a potent topoisomerase inhibitor. (abstract 1976). Proc. Am. Assoc. Cancer Res., 34, 332.
62. KANO Y, SUZUKI K, AKUTSU M, SUDA K, INOUE Y, YOSHIDA M, SAKAMOTO S AND MIURA Y. (1992). Effects of CPT-11 in combination with other anti-cancer agents in culture. Int. J. Cancer, 50, 604-610.
63. KANTARJIAN HM, BERAN M, ELLIS A, ZWELLING L, O'BRIEN S, CAZENAVE L, KOLLER C, RIOS MB, PLUNKETT W, KEATING MJ AND ESTEY EH. (1993). Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood, 81, 1146-1151.
64. KAUFMANN SH. (1991). Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res., 51, 1129-1136.
65. KAVANAGH JJ, KUDELKA AP, EDWARDS CE, GIRTANNER RE, DURIVAGE HF AND HOWELL ET. (1994). CPT-II (irinotecan): Phase II study in refractory squamous cell carcinoma of the cervix. Proc. Am. Assoc. Cancer Res., 35, 234.
66. KAWATO Y, AONUMA M, HIROTA Y, KUGA H AND SATO K, (1991a). Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res., 51, 4187 4191.
67. KAWATO Y, FURUTA T, AONUMA M, YASUOKA M, YOKOKURA T AND MATSUMOTO K. (1991b). Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother. Pharmacol., 28, 192 198.
68. KAWATO Y, SEKIGUCHI M, AKAHANE K, TSUTOMI Y, HIROTA Y, KUGA H, SUZUKI W, HAKUSUI H AND SATO K. (1993). Inhibitory activity of camptothecin derivatives against acetylcho-linesterase in dogs and their binding activity to acetylcholine receptors in rats. J. Pharm. Pharmacol., 45, 444 448.
69. KIM JH, KIM SH, KOLOZSVARY A AND KHIL MS. (1992). Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int. J. Rad. Oncol. Biol. Phys., 22, 515 518.
70. KIM R, HIRABAYSHI N, NISHIYAMA M, JINUSHI K, TOGE T AND OKADA K. (1992). Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumour xenografts in nude mice. Int. J. Cancer, 50, 760-766.
71. KUDELKA A, EDWARDS C, FREEDMAN R, WALLIN B, HORD M, HOWELL E, HARPER K, RABER M AND KAVANAGH J. (1993). An open phase II study to evaluate the efficacy and toxicity of topotecan administered intravenously as 5 daily infusions every 21 days to women with advanced epithelial ovarian carcinoma. (abstract 821). Proc. Am. Soc. Clin. Oncol., 12, 259.
72. KUNIMOTO T, NITTA K, TANAKA T, UEHARA N, BABA H, TAKEUCHI M, YOKOKURA T, SAWADA S, MIYASAKA T AND MUTAI M. (1987). Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res., 47, 5944-5947.
73. KURAISHI Y, SANO M, HIRANO A, DOBASHI N, MIZUNUMA N, FUNAKOSHI T, TAKASAKI N, KOBAUASHI T, ISOGAI Y, YAMASHITA T, AIBA K AND OGAWA M. (1992). In vitro combination effect of CPT-11, a new camptothecin derivative in human non-small cell lung cancer cell lines. (abstract 308). Proc. Am. Soc. Clin. Oncol., 11, 122.
74. LAW TM, ILSON DH AND MOTZER RJ. (1994). Phase II trial of topotecan in patients with advanced renal cell carcinoma. Invest. New Drugs, 12, 143 145.
75. LESTINGI TM, VOKES EE, GRAY W, SCHILSKY RL, VOGELZANG NJ, MICK R, GUPTA E AND RATAIN MJ. (1995). A phase I trial of CPT-11 in solid tumors with G-CSF and antidiarrheal support. (abstract 1536). Proc. Am. Soc. Clin. Oncol., 14, 480.
76. LYNCH TJJR, KALISH L, STRAUSS G, ELIAS A, SKARIN A, SHULMAN LN, POSNER M AND FREI E. (1994). Phase II study of topotecan in metastatic non-small-cell lung cancer. J. Clin. Oncol., 12, 347-352.
77. MCCABE FL AND JOHNSON RK. (1994). Comparative activity of oral and parenteral topotecan in murine tumor models: efficacy of oral topotecan. Cancer Invest., 12, 308-313.
78. MADDEN KR AND CHAMPOUX JJ. (1992). Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin. Cancer Res., 52, 525-532.
79. MAKSYMIUK AW, JUNG S-H, MARSCHKE RF, JR, NAIR S AND JETT JR. (1995). Phase II trial of topotecan in pleural mesothelioma: a North Central Cancer Treatment Group (NCCTG) trial. (abstract 1383). Proc. Am. Soc. Clin. Oncol., 14, 435.
80. MASUDA N, FUKUOKA M, KUSUNOKI Y, MATSUI K, TAKIFUJI N, KUDOH S, NEGORO S, NISHIOKA M, NAKAGAWA K AND TAKADA M. (1992). CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol., 10, 1225-1229.
81. MATTERN MR, HOFMANN GA, MCCABE FL AND JOHNSON RK. (1991). Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res., 51, 5813-5816.
82. MINAMI H, BEIJNAN JH, VERWEIJ J, RATAIN MJ. (1996). Limited sampling model for area under the concentration time curve of total topotecan. Clin Cancer Res., 2, 43-46.
83. MOERTEL CG, SCHUTT AJ, REITEMEIER RJ AND HAHN RG. (1972). Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep., 56, 95-101.
84. MUGGIA FM, CREAVEN PJ, HANSEN HH, COHEN MH AND SELAWRY OS. (1972). Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother. Rep., 56, 515 521.
85. MURPHY B, SALTZ L, SIROTT M, YOUNG C, TONG W, TROCHANOWSKI B, TOOMASI R AND KELSEN D. (1992). Granulocytecolony stimulating factor (G-CSF) does not increase the maximum tolerated dose (MTD) in a phase I study of topotecan. (abstract 379). Proc. Am. Soc. Clin. Oncol., 11, 139.
86. NARITA M, NAGAI E, HAGIWARA H, ABURADA M, YOKOI T AND KAMATAKI T. (1993). Inhibition of beta-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. Xenobiotica, 23, 5 10.
87. NEGORO S, FUKUOKA M, MASUDA N, TAKADA M, KUSUNOKI Y, MATSUI K, TAKIFUJI N, KUDOH S, NIITANI H AND TAGUCHI T. (1991a). Phase I study of weekly intravenous infusions of CPT-11. a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J. Nat. Cancer Inst., 83, 1164 1168.
88. NEGORO S, FUKUOKA M, NIITANI H, SUZUKI A, NAKABAYASHI T, KIMURA M, MOTOMIYA M, KURITA Y, HASEGAWA K, KURIYAMA T, NISHIWAKI Y, OGAWA M, NAKAO I, SAIJO N, OBA K, FURUE H, ARIYOSHI Y, SHIMOKATA K, FURUSE K, NAKAJIMA S, IRIE K, KIMURA I, OGURA T, FUJII M, HARA N, HARA Y, NAKAO S, ARAKI J, MIYATA Y, TAGUCHI T. (1991b). A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group. Gan to Kagaku Ryoho, 18, 1013-1019.
89. NIIMI S, NAKAGAWA K, SUGIMOTO Y, NISHIO K, FUJIWARA Y, YOKOYAMA S, TERASHIMA Y AND SAIJO N. (1992). Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer Res., 52, 328-333.
90. O'CONNOR PM, NIEVES-NEIRA W, KERRIGAN D, BERTRAND R, GOLDMAN J, KOHN KW AND POMMIER Y. (1991). S-phase population analysis does not correlate with the cytotoxicity of camptothecin and 10,11-methylenedioxycamptothecin in human colon carcinoma HT-29 cells. Cancer Commun., 3, 233 240.
91. O'DWYER P, CASSIDY J, KUNKA R, PAS-AREZ L, KAYE S, DEPEE S, LITTLEFIELD D, DEMARIA D, SELINGER K, BERANEK P, COLLIS P AND WISSEL P. (1995). Phase I trial of GG211, a new topoisomerase inhibitor, using a 72 hour continuous infusion (CI). (abstract 1525). Proc. Am. Soc. Clin. Oncol., 14, 471.
92. OHE Y, SASAKI Y, SHINKAI T, EGUCHl K, TAMURA T, KOJIMA A, KUNIKANE H, OKAMOTO H, KARATO A, OHMATSU H, KANAZAWA F AND NAGAHIRO S. (1992). Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J. Natl Cancer Inst., 84, 972 974.
93. OHNO R, OKADA K, MASAOKA T, KURAMOTO A, ARIMA T, YOSHIDA Y, ARIYOSHI H, ICHIMARU M, SAKAI Y, OGURO M, ITO Y, MORISHIMA Y, YOKOMAKU S AND OTA K. (1990). An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol., 8, 1907-1912.
94. OTA K, OHNO R, SHIRAKAWA S, MASAOKA T, OKADA K, OHASHI Y AND TAGUCHI T. (1994). Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematological Malignancies. Gan to Kagaku Ryoho, 21, 1047-1055.
95. PANTAZIS P, HINZ HR, MENDOZA JT, KOZIELSKI AJ, WILLIAMS LJ, JR, STEHLIN JS, JR, AND GIOVANELLA BC. (1992). Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res., 52, 3980-3987.
96. PEREZ-SOLER R, GLISSON BS, KANE J, LEE J, RABER MN AND HONG WK. (1994). Phase II study of topotecan in patients with non-small cell lung cancer (NSCLC) previously untreated. (abstract 1223). Proc. Am. Soc. Clin. Oncol., 13, 363.
97. PEREZ-SOLER R, GLISSON BS, LEE JS, FOSSELLA FV, LIPPMAN SM, HUBER MH, SHIN DM, MURPHY WK AND HONG WK. (1995). Phase II study of topotecan in patients with small cell lung cancer (SCLS) refractory to etoposide. (abstract 1078). Proc. Am. Soc. Clin. Oncol., 14, 355.
98. PITOT HC, WENDER D, O'CONNELL NJ, WIEAND HS AND MAILLIARD JA. (1994). A phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group (NCCTG) study. (abstract 573). Proc. Am. Soc. Clin. Oncol., 13, 197.
99. PLAXE S, CHRISTEN R, O'QUIGLEY J, BRALY P, FREDDO J, MCCLAY E, HEATH D AND HOWELL s. (1993). Phase I trial of intraperitoneal topotecan. (abstract 360). Proc. Am. Soc. Clin. Oncol., 12, 140.
100. POMMIER Y. (1993). DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother. Pharmacol., 32, 103-108.
101. POTKUL RK, PRICE FV, BAILEY H, GELDER M, ROSENBLUTH R AND DURIVAGE HJ. (1995). Irinotecan (CPT-11) in advanced squamous cell carcinoma of the cervix (phase II). (abstract 785). Proc. Am. Soc. Clin. Oncol., 14, 279.
102. POTMESIL M. (1994). Camptothecins: from bench research to hospital wards. Cancer Res., 54, 1431-1439.
103. PRATT CB, STEWART C, SANTANA VM, BOWMAN L, FURMAN W, OCHS J, MARINA N, KUTTESCH JF, HEIDEMAN R, SANDLUND JT, AVERY L AND MEYER WH. (1994). Phase I study of topotecan for pediatric patients with malignant solid tumors. J. Clin. Oncol., 12, 539-543.
104. ROBERT F, WHEELER RH, MOLTHROP DC, GREENE P AND CHEN S. (1994). Phase II study of topotecan in advanced head and neck cancer: identification of an active new agent. (abstract 905). Proc. Am. Soc. Clin. Oncol., 13, 281.
105. ROTHENBERG ML, KUHN JG, BURRIS HA, NELSON J, ECKARDT JR, TRISTAN-MORALES M, HILSENBECK SG, WEISS GR, SMITH LS, RODRIGUEZ GI, ROCK MK AND VON HOFF DD (1993). Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol., 11, 2194-2204.
106. ROTHENBERG ML, ECKARDT JR, BURRIS HA, III, NELSON J, KUHN JG, CHEN SF, HILSENBECK SB, CLARK GM, FIELDS SM, RODRIGUEZ GI, WEISS GR, SMITH LS, THURMAN AM, ECKHARDT SG, RINALDI DA, PEREZ E AND VON HOFF DD. (1994). Irinotecan (CPT-11) as second-line therapy for patients with 5-FU refractory colorectal cancer. (abstract 578). Proc. Am. Soc. Clin. Oncol., 13, 198.
107. ROUGIER PH, CULINE S, BUGAT R, BRUNET P, DOUILLARD JY, YCHOU M, MARTY M, BONNETERRE J, GANEM G, SEITZ JF, NEGRIER S, NAMER M, CONROY T, BURKI F, SHEARRER A, DROZ JP, MATHIEU-BOUE A, MAHJOUBI M AND HERAIT P. (1994). Multicentric phase II study of first line CPT-11 (irinotecan) in advanced colorectal cancer (CRC). (abstract 585). Proc. Am. Soc. Clin. Oncol., 13, 200.
108. ROWINSKY EK, GROCHOW LB, HENDRICKS CB, ETTINGER DS, FORASTIERE AA, HUROWITZ LA. MCGUIRE WP, SARTORIUS SE, LUBEJKO BG, KAUFMANN SH AND DONEHOWER RC (1992). Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J. Clin. Oncol., 10, 647-656.
109. ROWINSKY EK, GROCHOW LB, ETTINGER DS, SARTORIUS SE, LUBEJKO BG, CHEN TL, ROCK MK AND DONEHOWER RC (1994a). Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninetyminute infusion every 3 weeks. Cancer Res., 54, 427-436.
110. ROWINSKY E, GROCHOW L, KAUFMANN S, BOWLING K, BUBEJKO B, CHEN T, ETTINGER D, PEEREBOOM D, SARTORIUS S AND DONEHOWER R. (1994b). Sequence-dependent effects of topotecan (T) and cisplatin (C) in a phase I and pharmacology study. (abstract 468). Ann. Oncol., 5, 192.
111. RUBIN E, WOOD V, BHARTI A, TRITES D, LYNCH C AND KUFE D. (1994). A phase I trial of 9-amino-camptothecin (9-AC). (abstract 1465). Proc. Am. Assoc. Cancer Res., 35, 245.
112. SABIERS JH, BERGER NA, BERGER SJ, HAAGA JR, HOPPEL LL AND WILLSON JKV. (1993). Phase I trial of topotecan administered as a 72 hour infusion. (abstract 2541). Proc. Am. Assoc. Cancer Res., 34, 426.
113. SAKATA Y, SHIMADA Y, YOSHINO M, KAMBE M, FUTATSUKI K, NAKAO I, OGAWA N, WAKUI A AND TAGUCHI T. (1994). A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 Study Group on Gastrointestinal Cancer. Gan to Kagaku Ryoho, 21, 1039-1046.
114. SALTZ L, SIROTT M, YOUNG C, TONG W, NIEDZWIECKI D, TZYJYUN Y, TAO Y, TROCHANOWSKI B, WRIGHT P, BARBOSA K, TOOMASI F AND KELSEN D. (1993). Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumours, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J. Natl Cancer Inst., 85, 1499-1507.
115. SCHER R, LUSCH CJ, GREEN F, KOSIEROWSKI R, SIMMONDS M, ENGSTROM PF AND O'DWYER PJ. (1994). Phase II trial of topotecan in advanced pancreatic cancer. (suppl.5, abstract 463). Ann. Oncol., 5, 191.
116. SCHILLER JH, KIM K, JOHNSON D AND THE EASTERN COOPERATIVE ONCOLOGY GROUP (1994). Phase II study of topotecan in extensive stage small cell lung cancer. (abstract 1093). Proc. Am. Soc. Clin. Oncol., 13, 330.
117. SHIMADA Y, YOSHINO M, WAKUI A, NAKAO I, FUTATSUKl K, SAKATA Y, KAMBE M, TAGUCHI T AND OGAWA N. (1993). Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J. Clin. Oncol., 11, 909-913.
118. SLICHENMYER WJ, ROWINSKY EK, DONEHOWER RC AND KAUFMANN SH. (1993). The current status of camptothecin analogues as antitumor agents. J. Natl Cancer Inst., 85, 271-291.
119. SUGARMAN SM, AJANI JA, DAUGHERTY K, WINN R, LANZOTTI V, BEARDEN JD AND ABBRUZZESE LL. (1994a). A phase II trial of topotecan (TPT) for the treatment of advanced, measurable colorectal cancer. (abstract 686). Proc. Am. Soc. Clin. Oncol., 13, 225.
120. SUGARMAN SM, PAZDUR R, DAUGHERTY K, EVANS D, WINN R, DUBOVSKY D, GOODWIN JW AND ABBRUZZESE JL. (1994b). A phase II trial of topotecan (TPT) for the treatment of unresectable pancreatic cancer (PC). (abstract 684). Proc. Am. Soc. Clin. Oncol., 13, 224.
121. SUGIMOTO Y, TSUKAHARA S, OH-HARA T, LIU LF AND TSURUO T. (1990a). Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res., 50, 7962-7965.
122. SUGIMOTO Y, TSUKAHARA S, OH-HARA T, ISOE T AND TSURUO T. (1990b). Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res., 50, 6925-6930.
123. SUPKO JG AND MALSPEIS L. (1993). Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice. Cancer Res., 53, 3062-3069.
124. TAGUCHI T, WAKUI A, HASEGAWA K, NIITANI H, FURUE H, OHTA K AND HATTORI T. (1990). Phase I clinical study of CPT-11. Research group of CPT-11. Gan to Kagaku Ryoho, 17, 115 120.
125. TAGUCHI T, TOMINAGA T, OGAWA M, ISHIDA T, MORIMOTO K AND OGAWA N. (1994). A late phase II study of CPT-11 (irinotecan) in advanced breast cancer. CPT-11 Study Group on Breast Cancer. Gan to Kagaku Ryoho. 21, 1017 1024.
126. TAKEUCHI S, DOBASHI K, FUKIMOTO S, TANAKA K, SUZUKI M, TERASHIMA Y, HASUMI K, AKIYA K, NEGISHI Y, TAMAYA T AND ET AL. (1991). A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers. Gan to Kagaku Ryoho. 18, 1681 1689.
127. TAKIMOTO CH, KLECKER RW, DAHUT WL, BRILLHART N, YEE LK, STRON JM, NAKASHIMA H, LIEBERMAN R, ALLEGRA CJ AND GREM JL. (1994). Preliminary pharmacokinetics of the active lactone form of 9-aminocamptothecin using a sensitive new HPLC assay. (abstract 1443). Proc. Am. Assoc. Cancer Res., 35, 242.
128. TAN KB, MATTERN MR, ENG WK, MCCABE FL AND JOHNSON RK. (1989). Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J. Natl Cancer Inst., 81, 1732-1735.
129. TANIZAWA A, BEITRAND R, KOHLHAGEN G, TABUCHI A, JENKINS J AND POMMIER Y. (1993). Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. J. Biol. Chem., 268, 25463-25468.
130. TANIZAWA A, FUJIMORI A, FUJIMORI Y AND POMMIER Y. (1994). Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl Cancer Inst., 86, 836-842.
131. TEN BOKKEL HUININK WW, RODENHUIS S, BEIJNEN J, DUBBELMAN R AND KOIER I. (1992). Phase I study of the topoisomerase I inhibitor topotecan (SK & F 104864-A). (abstract 260). Proc. Am. Soc. Clin. Oncol., 11, 110.
132. TSURUO T, MATSUZAKI T, MATSUSHITA M, SAITO H AND YOKOKURA T. (1988). Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol., 21, 71-74.
133. TUBERGEN D, PRATT C, STEWART C AND VIETTI T. (1994). Phase I study of topotecan in children with refractory solid tumors: a pediatric oncology group study. (abstract 463). Proc. Am. Soc. Clin. Oncol., 13, 167.
134. VAN DER ZEE AG, DEJONG S, KEITH WN, HOLLEMA H, BOONSTRA H AND DE VRIES EG. (1991). P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/ cyclophosphamide chemotherapy. Cancer Res., 51, 5915-5920.
135. VERWEIJ J, LUND B, BEIJNEN J, PLANTING A, DE BOER-DENNERT M, KOIER I, ROSING H AND HANSEN H. (1993). Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann. Oncol., 4, 673-678.
136. WAGENER DJTH, WANDERS J, DIRIX LY, CATIMEL G, SIEGENTHALER P, FRANKLIN H AND VERWEIJ J. (1994). Phase II trial of CPT-11 in patients with advanced pancreatic cancer. (suppl.5, abstract 459). Ann. Oncol., 5, 190.
137. WALL ME, WANI MC, COOK CE, PALMER KH, MCPHAIL AT AND SIM GA. (1966). A. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc., 88, 3888-3889.
138. WALL JG, BURRIS HA, VON HOFF DD, RODRIGUEZ G, KNEUPERHALL R, SHAFFER D, O'ROURKE T, BROWN T, WEISS G, CLARK G AND ET AL. (1992). A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor lopotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anti-Cancer Drugs, 3, 337-345.
139. WALL ME, WANI MC, NICHOLAS AW, MANIKUMAR G, TELE C, MOORE L, TRUESDALE A, LEITNER P AND BESTERMAN JM. (1993). Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogues. J. Med. Chem., 36, 2689-2700.
140. WALTON MI, WHYSONG D, O'CONNOR PM, HOCKENBERY D, KORSMEYER SJ AND KOHN KW. (1993). Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res., 53, 1853-1861.
141. WANDERS J, ARDIZZONI A, HANSEN HH, DOMBERNOWSKY P, POSTMUS PE, BUITENHUIS M, MCDONALD M, GIACCONE G, VERWEIJ J. on behalf of the EORTC-ECTG and EORTC-LCCG. (1995). Phase II study of topotecan in refractory and sensitive small cell lung cancer. (abstract 1415). Proc. Am. Soc. Clin. Oncol., 36, 237.
142. WANI MC, RONMAN PE, LINDLEY JT AND WALL ME. (1980). Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues. J. Med. Chem., 23, 554-560.
143. WANI MC, NICHOLAS AW, MANIKUMAR G AND WALL ME. (1987). Plant antitumor agents. 25. Total synthesis and antileukemic activity of ring A substituted camptothecin analogues. Structure activity correlations. J. Med. Chem., 30, 1774-1779.
144. WEITZ JJ, JUNG S-H, MARSCHKE RF, Jr, FITCH TR AND JETT JR. (1995). Randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung carcinoma (NSCLC): a North Central Cancer Treatment Group (NCCTG) trial. (abstract 1053). Proc. Am. Soc. Clin. Oncol., 14, 348.
145. WOESSNER RD, ENG WK, HOFMANN GA, RIEMAN DJ, MCCABE FL, HERTZBERG RP, MATTERN MR, TAN KB AND JOHNSON RK. (1992). Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol. Res., 4, 481-488.
146. ZHANG H, D'ARPA P AND LIU LF. (1990). A model for tumor cell killing by topoisomerase poisons. Cancer Cells, 2, 23 27.